Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.47 |
| ▸ | MGAM | O43451 | 4/20 | 0.44 |
| ▸ | SI | P14410 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | PYGB | P11216 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18232569 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL14408063 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL13148198 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL13779601 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL17464420 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL277355 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL18349325 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL22058805 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL20798403 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 | |
| SCHEMBL12082884 | 1.00 | LGALS8 (0.47) | LGALS8MGAMSIGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624129-B2 | Inerting process for impurities | LAFARGE (FR) | 2017-04-18 | — | — | US | disclosed |
| US-20120216723-A1 | INERTING PROCESS FOR IMPURITIES | LAFARGE (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120216723-A1 | INERTING PROCESS FOR IMPURITIES | LAFARGE (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120123112-A1 | REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS PRODUCED IN A HALOGENATED IONIC LIQUID PROCESS AND PRODUCTS PRODUCED THEREFROM | EASTMAN CHEMICAL COMPANY (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120041080-A1 | CELLULOSE SOLUTIONS COMPRISING TETRAALKYLAMMONIUM ALKYLPHOSPHATE AND PRODUCTS PRODUCED THEREFROM | EASTMAN CHEMICAL COMPANY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090203898-A1 | CELLULOSE ESTERS AND THEIR PRODUCTION IN HALOGENATED IONIC LIQUIDS | EASTMAN CHEMICAL COMPANY (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041080-A1 | CELLULOSE SOLUTIONS COMPRISING TETRAALKYLAMMONIUM ALKYLPHOSPHATE AND PRODUCTS PRODUCED THEREFROM | AGPS, THEM6, PCTP | LGALS8 377/4885MGAM 12/4885SI 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.